MedTrace Logo

A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

NCT02391623 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-03-02

No results posted yet for this study

Summary

PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06427878 in healthy adult subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

PF-06427878

PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).

DRUG

Placebo

Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).

DRUG

PF-06427878

PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).

DRUG

Placebo

Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02391623 on ClinicalTrials.gov